Even after stopping apitegromab, the muscle-preserving effect lasts for at least two months, with users still retaining nearly 1 kilogram more muscle than those who never took it.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether the persistence of lean mass preservation after discontinuation is a consistent feature across different myostatin inhibitors and populations.
A systematic review and meta-analysis of all trials reporting lean mass outcomes after discontinuation of myostatin inhibitors during weight-loss therapy, pooling data from at least 5 studies with follow-up beyond 4 weeks post-treatment to assess durability of effect.
An RCT would confirm whether the 0.9 kg residual effect at week 32 is reproducible and whether it translates into sustained functional benefits.
A double-blind RCT of 200 adults with overweight or obesity randomized to 24 weeks of apitegromab plus tirzepatide followed by 8 weeks of washout versus placebo, with primary outcome being lean mass at week 32 and secondary outcomes including muscle strength and metabolic rate, repeated in a second cohort with extended follow-up to week 52.
A cohort study would determine whether the residual lean mass effect correlates with long-term physical function or metabolic health.
A prospective cohort study following 400 adults who received apitegromab for 24 weeks and discontinued, measuring lean mass, grip strength, and gait speed at 12, 24, and 36 months to assess whether the early preservation effect predicts long-term functional outcomes.
A cross-sectional study would estimate the prevalence of residual lean mass preservation in individuals who previously received apitegromab.
A cross-sectional analysis of 500 adults who previously received apitegromab for at least 24 weeks and discontinued for 8–24 weeks, measuring current lean mass via DXA and comparing it to matched controls who never received the drug.
A case report would document an individual with unusually prolonged lean mass preservation after a single course of apitegromab.
A case report series of 5 individuals who received a single 24-week course of apitegromab and maintained >0.8 kg more lean mass than baseline 12 months after discontinuation, with detailed documentation of physical activity, diet, and metabolic markers.